- Home
- ANEB vs YI Comparison
ANEB vs YI Comparison
Compare ANEB & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- YI
- Stock Information
- Founded
- ANEB 2020
- YI 2010
- Country
- ANEB United States
- YI China
- Employees
- ANEB N/A
- YI N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- ANEB Health Care
- YI Consumer Staples
- Exchange
- ANEB Nasdaq
- YI Nasdaq
- Market Cap
- ANEB 79.9M
- YI 69.4M
- IPO Year
- ANEB 2021
- YI N/A
- Fundamental
- Price
- ANEB $1.93
- YI $0.78
- Analyst Decision
- ANEB Buy
- YI
- Analyst Count
- ANEB 1
- YI 0
- Target Price
- ANEB $8.00
- YI N/A
- AVG Volume (30 Days)
- ANEB 13.3K
- YI 598.7K
- Earning Date
- ANEB 11-12-2024
- YI 11-28-2024
- Dividend Yield
- ANEB N/A
- YI N/A
- EPS Growth
- ANEB N/A
- YI N/A
- EPS
- ANEB N/A
- YI N/A
- Revenue
- ANEB N/A
- YI $2,026,540,888.00
- Revenue This Year
- ANEB N/A
- YI $61.85
- Revenue Next Year
- ANEB N/A
- YI N/A
- P/E Ratio
- ANEB N/A
- YI N/A
- Revenue Growth
- ANEB N/A
- YI 0.38
- 52 Week Low
- ANEB $1.72
- YI $0.55
- 52 Week High
- ANEB $3.30
- YI $2.49
- Technical
- Relative Strength Index (RSI)
- ANEB 49.10
- YI 45.55
- Support Level
- ANEB $1.83
- YI $0.75
- Resistance Level
- ANEB $1.96
- YI $1.00
- Average True Range (ATR)
- ANEB 0.08
- YI 0.11
- MACD
- ANEB 0.00
- YI -0.02
- Stochastic Oscillator
- ANEB 49.09
- YI 7.16
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.